The company focuses on developing a novel class of small-molecule drugs that target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Hemispherian has raised €14M across 3 funding rounds from 5 investors, most recently a Series A round in Nov 2022. Based in Oslo, Norway; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-11-24 | Series A | €2.8M | Kistefos,Kvantia,Meneldor,Steven Powell | View deal → |
| 2022-10-19 | Other | €10M | European Innovation Council (EIC) | View deal → |
| 2022-05-03 | Seed | €1.3M | Meneldor | View deal → |
